Condition: Hypoxic-Ischemic Encephalopathy · Sponsor: ReAlta Life Sciences, Inc.
Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.
This description comes directly from the study's public registry record.
Lori Upham · 757-901-0331 · Lupham@realtals.com
Always discuss trial participation with your own doctor first.
| Study Site 016 | Little Rock, Arkansas, United States | Recruiting |
| Study Site 013 | Orange, California, United States | Recruiting |
| Study Site 020 | San Diego, California, United States | Recruiting |
| Study Site 019 | San Diego, California, United States | Recruiting |
| Study Site 001 | Gainesville, Florida, United States | Recruiting |
| Study Site 018 | Miami, Florida, United States | Recruiting |
| Study Site 010 | Orlando, Florida, United States | Recruiting |
| Study Site 014 | Indianapolis, Indiana, United States | Recruiting |
| Study Site 012 | Lexington, Kentucky, United States | Withdrawn |
| Study Site 002 | Boston, Massachusetts, United States | Recruiting |
| Study Site 006 | St Louis, Missouri, United States | Recruiting |
| Study Site 003 | Durham, North Carolina, United States | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05778188